CLDI

Calidi Biotherapeutics, Inc. CLDI

NYSESmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$89.3K total
GEODE CAPITAL MANAGEMENT, LLC
$19.5K+81.8%
HighTower Advisors, LLC
$14.2K0.0%
JANE STREET GROUP, LLC
$9.2K+56.0%
Independent Advisor Alliance
$7.7KNew
RS CRUM INC.
$7.4K+7.4%
SRS Capital Advisors, Inc.
$6.3K0.0%
Private Advisor Group, LLC
$5.1KNew
VANGUARD CAPITAL MANAGEMENT LLC
$4.3K0.0%
Belpointe Asset Management LLC
$3.4K0.0%
NORTHERN TRUST CORP
$3.0K0.0%
MORGAN STANLEY
$2.3K+39.9%
RFG Advisory, LLC
$2.0KNew
Farther Finance Advisors, LLC
$1.7K0.0%
UBS Group AG
$1.3KNew
CITIGROUP INC
$781New
OSAIC HOLDINGS, INC.
$450+25.8%
Tower Research Capital LLC (TRC)
$2370.0%
Finepoint Capital LP
$1770.0%
HIGHBRIDGE CAPITAL MANAGEMENT LLC
$1770.0%
SBI Securities Co., Ltd.
$64+226.1%
Tradewinds Capital Management, LLC
$180.0%
Reyes Financial Architecture, Inc.
$170.0%
EVERMAY WEALTH MANAGEMENT LLC
$10.0%
See all 23 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CLDI

Earnings Per Share

13fpro.ai/company/CLDI

Loading ratio trend…

CLDI key financials by period

Reported revenue, net income and operating margin by fiscal year, from Calidi Biotherapeutics, Inc.'s annual filings on SEC EDGAR.

Calidi Biotherapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2022$45.0K$-25.4M—
Source: CLDI filings on SEC EDGAR →

CLDI insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Calidi Biotherapeutics, Inc. (CLDI): stock profile, AI score and financials

Calidi Biotherapeutics, Inc. (CLDI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CLDI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of CLDI by reported 13-F value include GEODE CAPITAL MANAGEMENT, HighTower Advisors, JANE STREET GROUP, based on the most recent SEC filings. CLDI trades on the NYSE exchange and files with the SEC under CIK 1855485. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLDI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Calidi Biotherapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1855485 →